The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | New approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses new approaches to treating patients with multiple myeloma (MM) who are transplant-ineligible, particularly focusing on elderly individuals who have poor outcomes. Triplet therapies combining proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and/or anti-CD30 antibodies show improved efficacy compared to doublets. Ongoing trials are exploring quadruplet combinations (IMROZ: NCT03319667; BENEFIT: NCT04751877; GEM2017FIT: NCT03742297), aiming to identify which patients benefit most from these intensive regimens. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
